research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
Search
for
Sort by
Research
660-690 / 1000+ results
research Obstetrician/Gynecologist
I'm sorry, but there's not enough information to provide a summary.
research Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between Vitamin D Receptor and Hairless Protein
Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research 1465 Optimization/characterization of a Focal Dermal Hypoplasia mouse model to test potential treatments
Li2CO3 improved skin disease in a mouse model of Focal Dermal Hypoplasia without toxicity.
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series
Low-dose oral minoxidil is an effective and well-tolerated treatment for hair growth in alopecia patients.
research Re: Dermmatch, Inc.
research Therapy of Acute Myeloid Leukemia
Treating acute myeloid leukemia is challenging, especially in older adults, despite some advancements.
research Follow-up
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Faculty Opinions recommendation of Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Low-dose oral minoxidil is a promising, safe treatment for various hair diseases, improving hair thickness and density, but more research is needed on long-term side effects and treatment duration.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Diffuse hair loss in Addison disease: A reason for X-linked adrenoleukodystrophy screening
Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.
research This Month in Clinical Urology
New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
research First Report on Microbial-Derived Polydeoxyribonucleotide: A Sustainable and Enhanced Alternative to Salmon-Based Polydeoxyribonucleotide
Microbial-derived polydeoxyribonucleotide is a better and more sustainable alternative to salmon-based versions for healing and immune support.
research OsCSLD1 Mediates NH4+-Dependent Root Hair Growth Suppression and AMT1;2 Expression in Rice (Oryza sativa L.)
CSLD1 suppresses rice root hair growth with NH4+ and regulates AMT1;2 expression.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Mendeley Supplemental Document 1
research A Method to Monitor Dutasteride in Rat Plasma Using Liquid-Liquid Extraction and Multiple Reaction Monitoring: Comparisons and Validation
The best method to monitor dutasteride in rat plasma is liquid-liquid extraction with methyl tert-butyl ether and methylene chloride.
research Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review
The safety and tolerability of low-dose oral minoxidil for treating hair loss in adolescents is not clearly determined.
research THE INFLUENCE OF ALLOXAN DIABETES, METHYLTHIOURACIL, CORTISONE AND ADRENALINE ON THE UTILIZATION OF GLUCOSE 14C AND L-CYSTINE 35S AND MITOTIC ACTIVITY BY HAIR FOLLICLES IN WHITE MICE
Alloxan diabetes, methylthiouracil, cortisone, and adrenaline affect how white mice hair follicles use glucose and cystine and their cell division.
research GŁÓWNE TRUDNOŚCI W OPANOWANIU POLSKIEGO SŁOWNICTWA SPECJALISTYCZNEGO PRZEZ MEDYKÓW ZE WSCHODU
Eastern medical professionals struggle with Polish specialized vocabulary due to language differences, and tailored educational materials could help.
research Formulation of Deformable Liponiosomal Hybrid of Repaglinide: In vitro Characterization and Evaluation of the Anti-Diabetic Effect
Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
research Wavelength-encoded laser particles for massively-multiplexed cell tagging
New laser particles can track thousands of cells in 3D models, improving single-cell analysis.
research 83 Transcriptomic meta-analysis and deconvolution approaches unveil cellular dynamics in scarring and non-scarring primary lymphocytic alopecias
research Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review
There is a significant need for better-validated quality of life tools in dermatology.
research LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.